• Publications
  • Influence
Mutation in TET2 in myeloid cancers.
To the Editor: The finding of Delhommeau and colleagues that TET2 mutations occur in myeloid cancers (May 28 issue)1 has been confirmed by others.2-5 The presence of single-copy and doublecopy TET2Expand
  • 493
  • 44
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which complicates prognostication and decision making regarding the choice and timing of therapy. In a retrospective study ofExpand
  • 270
  • 17
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
The prognostic heterogeneity of the World Health Organization category of "systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease" (SM-AHNMD) has not beenExpand
  • 131
  • 9
  • PDF
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
STUDY OBJECTIVES The prevalence of epidermal growth factor receptor (EGFR) mutations in gefitinib-naive lung cancer patients is higher in adenocarcinomas, in women, and in Japanese. To furtherExpand
  • 114
  • 3
Cyclosporine in the treatment of dermatologic disease: an update.
Treatment with cyclosporine is beneficial for many dermatologic diseases such as psoriasis, lichen planus, Behçet disease, atopic dermatitis, pyoderma gangrenosum, and epidermolysis bullosaExpand
  • 54
  • 2
WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults.
To the editor: The 2008 World Health Organization (WHO) proposal recognizes 2 provisional indolent systemic mastocytosis (ISM) subvariants: smoldering systemic mastocytosis (SSM) and isolated boneExpand
  • 54
  • 2
  • PDF
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
Most gastrointestinal stromal tumors (GISTs) are associated with activating kinase mutation in KIT or platelet-derived growth factor receptor alpha (PDGFRA) gene, and imatinib has revolutionized theExpand
  • 42
  • 1
Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer
PurposeTo investigate the prognostic value of epidermal growth factor receptor (EGFR) mutations in a series of Taiwanese patients with primary resected lung adenocarcinomas never treated withExpand
  • 23
  • 1
Primary carcinoid tumor of prostate presenting with bone marrow metastases.
Primary carcinoid tumor of the prostate is a rare tumor derived from the amine precursor uptake and decarboxylation cells of the prostate. We report a case of a 71-year-old man who presented withExpand
  • 18
  • 1